ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2020
Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02372773 (Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects), which is not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- The presymptomatic phase of amyotrophic lateral sclerosis: are we merely scratching the surface?Journal of neurology · 2021Pooled it
- Effects of open-label transdermal nicotine antidepressant augmentation on affective symptoms and executive function in late-life depression.Journal of affective disorders · 2024Trial
- Factors influencing accelerated progression in behavioral variant frontotemporal dementia.Journal of neurology · 2026Article
- Tablet-based Cognitive Assessment Tool (TabCAT) in a multisite study of early-onset Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Design considerations for C9orf72 disease prevention trials.Brain : a journal of neurology · 2025Review
- Executive Function Deficits in Genetic Frontotemporal Dementia: Results From the GENFI Study.Neurology. Genetics · 2025Article
- Bringing Executive Function Testing Online: Assessment Validation Study.JMIR formative research · 2025Article
- Screening for Executive Impairment in Patients with Frontotemporal Dementia: Evidence from the Greek Version of the Frontier Executive Screen.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2025Article
- Development and validation of the TabCAT-EXAMINER: A tablet-based executive functioning battery for research and clinical trials.Journal of the International Neuropsychological Society : JINS · 2025Article
- Gene-Specific Effects on Brain Volume and Cognition ofNeurology · 2024Article
- Better cardiovascular health is associated with slowed clinical progression in autosomal dominant frontotemporal lobar degeneration variant carriers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Reliability and Validity of Smartphone Cognitive Testing for Frontotemporal Lobar Degeneration.JAMA network open · 2024Article
- Vessel density mapping of small cerebral vessels on 3D high resolution black blood MRI.NeuroImage · 2024Article
- Changes in Digital Speech Measures in Asymptomatic Carriers of Pathogenic Variants Associated With Frontotemporal Degeneration.Neurology · 2024Article
- Diagnostic accuracy of research criteria for prodromal frontotemporal dementia.Alzheimer's research & therapy · 2024Article
- The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials.Frontiers in aging neuroscience · 2024Article
- Microglial activation in the frontal cortex predicts cognitive decline in frontotemporal dementia.Brain : a journal of neurology · 2023Article
- Temporal order of clinical and biomarker changes in familial frontotemporal dementia.Nature medicine · 2022Article
- Proposed research criteria for prodromal behavioural variant frontotemporal dementia.Brain : a journal of neurology · 2022Article
- Cognitive composites for genetic frontotemporal dementia: GENFI-Cog.Alzheimer's research & therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
93 authors at 20 institutions in 2 countries.
Adam M StaffaroniDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Lynn BajorekDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Kaitlin B CasalettoDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Yann CobigoDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Sheng-Yang M GohDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Amy WolfDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Hilary W HeuerDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Fanny M ElahiDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Peter A LjubenkovDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Reilly DeverDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
John KornakDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Brian ApplebyDepartment of Neurology, Case Western Reserve University, Cleveland, OH, USA.
Jessica BoveDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Yvette BordelonDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Patrick BrannellyTau Consortium, Rainwater Charitable Foundation, Fort Worth, TX, USA.
Danielle BrushaberDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Christina CasoDepartment of Neurology, University of Washington, Seattle, WA, USA.
Giovanni CoppolaDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Christina DheelDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Bradford C DickersonDepartment of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Susan DickinsonAssociation for Frontotemporal Degeneration, Radnor, PA, USA.
Sophia DominguezDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Kimiko Domoto-ReillyDepartment of Neurology, University of Washington, Seattle, WA, USA.
Kelly FaberNational Cell Repository for Alzheimer's Disease (NCRAD), Indiana University, Indianapolis, IN, USA.
Jessica FerrallDepartment of Neurology, University of North Carolina, Chapel Hill, NC, USA.
Julie A FieldsDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Ann FishmanSchool of Medicine, Department of Psychiatry, Johns Hopkins University, Baltimore, MD, USA.
Jamie FongDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Tatiana ForoudNational Cell Repository for Alzheimer's Disease (NCRAD), Indiana University, Indianapolis, IN, USA.
Leah K ForsbergDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Ralitza GavrilovaDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Debra GearhartDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Behnaz GhazanfariTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
Nupur GhoshalDepartments of Neurology and Psychiatry, Washington University School of Medicine, Washington University, St. Louis, MO, USA.
Jill GoldmanDepartment of Neurology, Columbia University, New York, NY, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Neill Graff-RadfordDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Ian GrantFeinberg School of Medicine, Department of Neurology, Northwestern University, Chicago, IL, USA.
Murray GrossmanDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Dana HaleyDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Ging-Yuek HsiungDivision of Neurology, Deptartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Edward D HueyDepartment of Neurology, Columbia University, New York, NY, USA.
David J IrwinDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
David T JonesDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Lynne JonesDepartment of Radiology, Washington University School of Medicine, Washington University, St. Louis, MO, USA.
Kejal KantarciDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Anna KarydasDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Daniel I KauferDepartment of Neurology, University of North Carolina, Chapel Hill, NC, USA.
Diana R KerwinDepartment of Neurology and Neurotherapeutics, Center for Alzheimer's and Neurodegenerative Diseases, The University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, USA.
David S KnopmanDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Ruth KraftDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Walter K KremersDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Walter A KukullNational Alzheimer Coordinating Center (NACC), University of Washington, Seattle, WA, USA.
Irene LitvanDepartment of Neurosciences, Parkinson and Other Movement Disorders Center, University of California, San Diego, San Diego, CA, USA.
Diane LucenteDepartment of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Codrin LunguNational Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD, USA.
Ian R MackenzieDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Miranda MaldonadoDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Masood ManoochehriDepartment of Neurology, Columbia University, New York, NY, USA.
Scott M McGinnisDepartment of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Emily McKinleyDepartment of Neurology, Alzheimer's Disease Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Mario F MendezDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Bruce L MillerDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Namita MultaniTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
Chiadi OnyikeDepartment of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University, Baltimore, MD, USA.
Jaya PadmanabhanDepartment of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Alex PantelyatSchool of Medicine, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Rodney PearlmanBluefield Project, San Francisco, CA, USA.
Len PetrucelliDepartment of Neurosciences, Mayo Clinic, Jacksonville, FL, USA.
Madeline PotterNational Cell Repository for Alzheimer's Disease (NCRAD), Indiana University, Indianapolis, IN, USA.
Rosa RademakersDepartment of Neurosciences, Mayo Clinic, Jacksonville, FL, USA.
Eliana Marisa RamosDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
Katherine P RankinDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Katya RascovskyDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Erik D RobersonDepartment of Neurology, Alzheimer's Disease Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Emily RogalskiFeinberg School of Medicine, Department of Psychiatry and Behavioral Sciences, Northwestern University, Chicago, IL, USA.
Pheth SengdyDivision of Neurology, Deptartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Leslie M ShawPerelman School of Medicine, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jeremy SyrjanenDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
M Carmela TartagliaTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
Nadine TattonAssociation for Frontotemporal Degeneration, Radnor, PA, USA.
Joanne TaylorDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Arthur TogaDepartments of Ophthalmology, Neurology, Psychiatry and the Behavioral Sciences, Radiology and Engineering, Laboratory of Neuroimaging (LONI), USC, Los Angeles, CA, USA.
John Q TrojanowskiPerelman School of Medicine, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Sandra WeintraubFeinberg School of Medicine, Department of Neurology, Northwestern University, Chicago, IL, USA.
Ping WangDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Bonnie WongDepartment of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Zbigniew WszolekDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Adam L BoxerDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Brad F BoeveDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Joel H KramerDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Howard J RosenDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
ARTFL/LEFFTDS consortium
University Memory and Aging Center · USMayo Clinic in Arizona · USMayo Clinic in Florida · USUniversity of Pennsylvania · USUniversity of California, San Francisco · USMassachusetts General Hospital · USUniversity of California, Los Angeles · USColumbia University · USIndiana University – Purdue University Indianapolis · USNorthwestern University · USUniversity of British Columbia · CAUniversity of Washington · USAssociation for Frontotemporal Degeneration · USJohns Hopkins Medicine · USUniversity of Alabama at Birmingham · USUniversity of North Carolina at Chapel Hill · USUniversity of Toronto · CAWashington University in St. Louis · USBluefield College · USCase Western Reserve University · US
Funding
Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI Bradley F Boeve · 2019 to 2026
$120.9MNational Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8MNATIONAL ALZHEIMERS COORDINATING CENTER (NACC)U01AG016976 · NIA · UNIVERSITY OF WASHINGTON · PI KUKULL, WALTER ANTHONY · 1999 to 2020
$72.8MTDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2MTHERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI JAYADEY, SUMAN · 1985 to 2019
$57.2MSatellite Diagnostic and Treatment Clinic CoreP50AG008702 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DE JAGER, PHILIP L · 1989 to 2019
$46.3MNational Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8MTransgenic Mouse Models of Tau PathologiesP01AG017586 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LEE, VIRGINIA M · 2000 to 2021
$37.3MResearch Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5MUniversity of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI SUMAN JAYADEV · 2020 to 2026
$29.0MNeuropathology CoreP30AG013854 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BIGIO, EILEEN H. · 1996 to 2020
$28.9MUnderstanding Environmental Contributions to Heterogeneity in bvFTD.P01AG066597 · NIA · UNIVERSITY OF PENNSYLVANIA · PI David John Irwin, Corey T McMillan · 2020 to 2026
$18.8MAlzheimer's AssociationNIA NIH HHS K23 AG061253NIA NIH HHS K24 AG045333NIA NIH HHS P01 AG017586NIA NIH HHS P01 AG019724NIA NIH HHS P01 AG066597NIA NIH HHS P30 AG013854NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG066509NIA NIH HHS P50 AG005136NIA NIH HHS P50 AG008702NIA NIH HHS R01 AG032306NIA NIH HHS R01 AG038791NIA NIH HHS R01 AG062268NIA NIH HHS T32 AG023481NIA NIH HHS U01 AG016976NIA NIH HHS U01 AG045390NIA NIH HHS U19 AG063911NIA NIH HHS U24 AG021886NIA NIH HHS U24 AG072122NIH HHS AG045390NIMH NIH HHS R01 MH120794NINDS NIH HHS U54 NS092089
Abstract
introductionIdentifying clinical measures that track disease in the earliest stages of frontotemporal lobar degeneration (FTLD) is important for clinical trials. Familial FTLD provides a unique paradigm to study early FTLD. Executive dysfunction is a clinically relevant hallmark of FTLD and may be a marker of disease progression.
methodsNinety-three mutation carriers with no symptoms or minimal/questionable symptoms (MAPT, n = 31; GRN, n = 28; C9orf72, n = 34; Clinical Dementia Rating scale plus NACC FTLD Module < 1) and 78 noncarriers enrolled through Advancing Research and Treatment in Frontotemporal Lobar Degeneration/Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects studies completed the Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research (NIH-EXAMINER) and the UDS neuropsychological battery. Linear mixed-effects models were used to identify group differences in cognition at baseline and longitudinally. We examined associations between cognition, clinical functioning, and magnetic resonance imaging volumes.
resultsNIH-EXAMINER scores detected baseline and differences in slopes between carriers and noncarriers, even in carriers with a baseline Clinical Dementia Rating scale plus NACC FTLD Module = 0. NIH-EXAMINER declines were associated with worsening clinical symptoms and brain volume loss. DISCUSSION: The NIH-EXAMINER is sensitive to cognitive changes in presymptomatic familial FTLD and is a promising surrogate endpoint.
Indexed as
Disease ProgressionFrontotemporal DementiaBiomarkersC9orf72 ProteinExecutive FunctionFemaleHumansLongitudinal StudiesMagnetic Resonance ImagingMaleMiddle AgedMutationNeuropsychological TestsBiomarkersC9orf72 ProteinC9orf72 protein, humanBehavioral variantCognitionCorticobasal syndromeFluencyGeneticInhibitionNeuropsychologyNonfluent variantPrimary progressive aphasiaProgranulinProgressive supranuclear palsySemantic variantSet-shiftingTauWorking memory
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT02372773ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.